Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor.

The presence of nonalcoholic fatty liver disease often precludes potential organs from being used for transplantation. To date, there is no adequate treatment for hepatic steatosis, and it is expected that, because of increased obesity in Western society, the incidence of this disorder will increase. We investigated the effect of omega-3 polyunsaturated fatty acid supplementation on the treatment of hepatic steatosis in C57/Bl6 mice fed a high-carbohydrate, fat-free diet and in B6.V-Lep(ob) obese mice. Omega-3 fatty acid supplementation reversed hepatic steatosis in C57/Bl6 mice fed a high-carbohydrate, fat-free diet and converted macrovesicular to microvesicular steatosis in B6.V-Lep(ob) obese mice as determined by histology, magnetic resonance spectroscopy, and liver biochemistry We therefore conclude that omega-3 fatty acid supplementation improves hepatic steatosis in mice and may be used to increase the pool of potential live liver donors that are currently excluded because of the presence of macrovesicular steatosis.

[1]  D. Cooper,et al.  Xenotransplantation--how far have we come? , 2002, Transplant immunology.

[2]  Karl G Sylvester,et al.  Stem cells: review and update. , 2004, Archives of surgery.

[3]  G. Klintmalm,et al.  THE USE OF mARGINAL DONORS FOR LIVER TRANSPLANTATION A RETROSPECTIVE STUDY OF 365 LIVER DONORS 1,2 , 1992, Transplantation.

[4]  W. Jochum,et al.  Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. , 2003, Journal of Hepatology.

[5]  P. Mcmaster,et al.  Policies in Europe on "marginal quality" donor livers , 1994, The Lancet.

[6]  R. Tompkins,et al.  Technique for expanding the donor liver pool: Heat shock preconditioning in a rat fatty liver model , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  J. Clore,et al.  Dietary n‐3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats , 2004, Hepatology.

[8]  S. Kitano,et al.  ASSESSMENT OF DONOR FATTY LIVERS FOR LIVER TRANSPLANTATION1 , 2001, Transplantation.

[9]  R. Busuttil,et al.  The utility of marginal donors in liver transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  S. Fan,et al.  Safety of donors in live donor liver transplantation using right lobe grafts. , 2000, Archives of surgery.

[11]  Michael J Lysaght,et al.  Tissue engineering: the end of the beginning. , 2004, Tissue engineering.

[12]  A. Burke,et al.  Non‐Alcoholic Fatty Liver Disease, Non‐Alcoholic Steatohepatitis and Orthotopic Liver Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  R. Stratta,et al.  FROZEN SECTION EVALUATION OF DONOR LIVERS BEFORE TRANSPLANTATION , 1993, Transplantation.

[14]  V. Nosé,et al.  Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB‐1 suppression or by correcting essential fatty acid deficiency , 2004, Hepatology.

[15]  K. Sugimachi,et al.  Use of steatotic graft in living-donor liver transplantation , 2003, Transplantation.

[16]  T. Fishbein,et al.  Use of livers with microvesicular fat safely expands the donor pool. , 1997, Transplantation.

[17]  Zhaoli Sun,et al.  In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. , 2003, Gastroenterology.

[18]  J. Alvarez,et al.  Separation of acidic and neutral lipids by aminopropyl-bonded silica gel column chromatography. , 1992, Journal of chromatography.

[19]  T E Starzl,et al.  Primary nonfunction of hepatic allografts with preexisting fatty infiltration. , 1989, Transplantation.